节点文献

干扰素联合拉米夫定治疗慢性乙型肝炎的临床用药研究

Research of Clinical Application in Treating Chronic Hepatitis B with Interferon and Lamivudine

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 尚慧金颖石桂华

【Author】 SHANG Hui 1, JIN Ying 1, SHI Gui-hua 2(Institute of Shandong Medical Imaging, Jinan 250021, China; 2. Jinan Fi fth People’s Hospital, Jinan 250021, China)

【机构】 山东省医学影像学研究所济南市第五人民医院 山东济南250021山东济南250021山东济南250021

【摘要】 应用抗病毒药物干扰素和拉米夫定探索治疗乙肝的“鸡尾酒”疗法。将 90名慢性乙型肝炎患者分为甲、乙、丙 3组 ,每组 30例。甲组为联合用药组 ,乙组为干扰素组 ,丙组为拉米夫定组。结果干扰素 -拉米夫定联合治疗组疗效较佳 ,多个指标与其他两组比较有显著性差异。结论干扰素 -拉米夫定联合应用的疗效好于单一应用 ,能更有效抑制病毒复制 ,改善肝功能 ,并减少复发。

【Abstract】 A cocktail therapeusis to treat hepatitis B with ant iv irus drug interferon and lamivudine was studied. 90 chronic hepatitis B patients were divided into 3 groups: A, B and C. Each group included 30 patients. Group A was treated with both interferon and lamivudine, B with interferon and C with lamivudine. The result showed that the curative effect of group A (interferon-l amivudine group) was the best, with several targets significantly different with the other two groups. It was concluded that the therapy of combining interferon with lamivudine was better than using interferon or lamivudine only. The cockta il therapeusis can prevent the replication of virus, improve liver function and reduce the possibility of relapse of chronic hepatitis B.

  • 【文献出处】 药物生物技术 ,Pharmaceutical Biotechnology , 编辑部邮箱 ,2004年04期
  • 【分类号】R512.62
  • 【被引频次】1
  • 【下载频次】55
节点文献中: 

本文链接的文献网络图示:

本文的引文网络